Does the media prefer RCUS or ABUS?

In the previous week, Arcus Biosciences had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Arcus Biosciences and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Arcus Biosciences' score of 0.45 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABUS or DYN?

In the previous week, Dyne Therapeutics had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Dyne Therapeutics and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Dyne Therapeutics' score of 0.58 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GPCR or ABUS?

In the previous week, Arbutus Biopharma had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Arbutus Biopharma and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.61 beat Arbutus Biopharma's score of 0.99 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Arbutus Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABUS or BEAM?

In the previous week, Beam Therapeutics had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 12 mentions for Beam Therapeutics and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Beam Therapeutics' score of 0.70 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RLAY or ABUS?

In the previous week, Relay Therapeutics had 9 more articles in the media than Arbutus Biopharma. MarketBeat recorded 13 mentions for Relay Therapeutics and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Relay Therapeutics' score of 0.49 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arbutus Biopharma (ABUS) Competitors

$4.50 -0.11 (-2.28%)

As of 02:26 PM Eastern

Compare

ABUS vs. RCUS, DYN, GPCR, BEAM, and RLAY

Should you buy Arbutus Biopharma stock or one of its competitors? MarketBeat compares Arbutus Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arbutus Biopharma include Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Beam Therapeutics (BEAM), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

How does Arbutus Biopharma compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Arbutus Biopharma has a net margin of 83.95% compared to Arcus Biosciences' net margin of -156.36%. Arbutus Biopharma's return on equity of 129.32% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Arbutus Biopharma	83.95%	129.32%	112.24%

Arcus Biosciences has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

In the previous week, Arcus Biosciences had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Arcus Biosciences and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Arcus Biosciences' score of 0.45 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	14.19	-$353M	-$3.18	N/A
Arbutus Biopharma	$14.08M	63.20	-$33.50M	$0.83	5.43

Arcus Biosciences currently has a consensus price target of $35.10, indicating a potential upside of 25.95%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 10.99%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Arbutus Biopharma beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Dyne Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Arbutus Biopharma currently has a consensus target price of $5.00, suggesting a potential upside of 10.99%. Dyne Therapeutics has a consensus target price of $34.17, suggesting a potential upside of 43.89%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arbutus Biopharma has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	63.20	-$33.50M	$0.83	5.43
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Arbutus Biopharma has a net margin of 83.95% compared to Dyne Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Dyne Therapeutics and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Dyne Therapeutics' score of 0.58 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arbutus Biopharma beats Dyne Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Arbutus Biopharma has a net margin of 83.95% compared to Structure Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Arbutus Biopharma	83.95%	129.32%	112.24%

In the previous week, Arbutus Biopharma had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Arbutus Biopharma and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.61 beat Arbutus Biopharma's score of 0.99 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Arbutus Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics presently has a consensus price target of $110.55, suggesting a potential upside of 125.81%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential upside of 10.99%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Structure Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Structure Therapeutics has a beta of -1.5, indicating that its stock price is 250% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Arbutus Biopharma has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Arbutus Biopharma	$14.08M	63.20	-$33.50M	$0.83	5.43

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Arbutus Biopharma beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Beam Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Arbutus Biopharma has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	63.20	-$33.50M	$0.83	5.43
Beam Therapeutics	$139.74M	22.74	-$79.99M	-$0.68	N/A

Arbutus Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 10.99%. Beam Therapeutics has a consensus price target of $46.85, suggesting a potential upside of 51.64%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arbutus Biopharma has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

In the previous week, Beam Therapeutics had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 12 mentions for Beam Therapeutics and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Beam Therapeutics' score of 0.70 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a net margin of 83.95% compared to Beam Therapeutics' net margin of -39.66%. Arbutus Biopharma's return on equity of 129.32% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Arbutus Biopharma beats Beam Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Relay Therapeutics presently has a consensus target price of $23.73, indicating a potential upside of 21.90%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 10.99%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relay Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Arbutus Biopharma has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	242.95	-$276.48M	-$1.57	N/A
Arbutus Biopharma	$14.08M	63.20	-$33.50M	$0.83	5.43

Relay Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

In the previous week, Relay Therapeutics had 9 more articles in the media than Arbutus Biopharma. MarketBeat recorded 13 mentions for Relay Therapeutics and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.99 beat Relay Therapeutics' score of 0.49 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a net margin of 83.95% compared to Relay Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Arbutus Biopharma	83.95%	129.32%	112.24%

Summary

Relay Therapeutics beats Arbutus Biopharma on 9 of the 17 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$889.92M	$3.67B	$6.78B	$12.65B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	5.43	21.48	27.13	24.40
Price / Sales	63.20	327.86	525.28	91.46
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	11.26	8.55	10.85	6.33
Net Income	-$33.50M	$23.88M	$3.59B	$331.45M
7 Day Performance	-13.70%	-2.84%	-1.34%	0.18%
1 Month Performance	4.28%	5.93%	2.96%	-0.72%
1 Year Performance	43.93%	52.58%	28.93%	20.53%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	1.8326 of 5 stars	$4.51 -2.3%	$5.00 +11.0%	+42.3%	$889.92M	$14.08M	5.43	90
RCUS Arcus Biosciences	3.6149 of 5 stars	$29.99 -1.1%	$35.10 +17.0%	+194.4%	$3.81B	$247M	N/A	500	Insider Trade
DYN Dyne Therapeutics	3.2161 of 5 stars	$22.84 -1.0%	$34.17 +49.6%	+166.9%	$3.81B	N/A	N/A	100
GPCR Structure Therapeutics	2.612 of 5 stars	$54.75 +2.4%	$110.55 +101.9%	+158.5%	$3.80B	N/A	N/A	136	Positive News
BEAM Beam Therapeutics	3.4063 of 5 stars	$35.32 +1.5%	$46.83 +32.6%	+45.9%	$3.58B	$139.74M	N/A	510	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. RCUS, DYN, GPCR, BEAM, and RLAY

How does Arbutus Biopharma compare to Arcus Biosciences?

Summary

How does Arbutus Biopharma compare to Dyne Therapeutics?

Summary

How does Arbutus Biopharma compare to Structure Therapeutics?

Summary

How does Arbutus Biopharma compare to Beam Therapeutics?

Summary

How does Arbutus Biopharma compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. RCUS, DYN, GPCR, BEAM, and RLAY

How does Arbutus Biopharma compare to Arcus Biosciences?

Is RCUS or ABUS more profitable?

Which has more volatility & risk, RCUS or ABUS?

Does the media prefer RCUS or ABUS?

Do insiders and institutionals have more ownership in RCUS or ABUS?

Which has stronger valuation & earnings, RCUS or ABUS?

Do analysts prefer RCUS or ABUS?

Summary

How does Arbutus Biopharma compare to Dyne Therapeutics?

Do analysts recommend ABUS or DYN?

Which has more volatility & risk, ABUS or DYN?

Do institutionals and insiders hold more shares of ABUS or DYN?

Which has better earnings and valuation, ABUS or DYN?

Is ABUS or DYN more profitable?

Does the media prefer ABUS or DYN?

Summary

How does Arbutus Biopharma compare to Structure Therapeutics?

Is GPCR or ABUS more profitable?

Does the media prefer GPCR or ABUS?

Do analysts recommend GPCR or ABUS?

Which has more volatility and risk, GPCR or ABUS?

Which has higher valuation and earnings, GPCR or ABUS?

Do insiders and institutionals hold more shares of GPCR or ABUS?

Summary

How does Arbutus Biopharma compare to Beam Therapeutics?

Which has higher earnings & valuation, ABUS or BEAM?

Do analysts recommend ABUS or BEAM?

Do insiders & institutionals have more ownership in ABUS or BEAM?

Which has more risk & volatility, ABUS or BEAM?

Does the media refer more to ABUS or BEAM?

Is ABUS or BEAM more profitable?

Summary

How does Arbutus Biopharma compare to Relay Therapeutics?

Do insiders and institutionals believe in RLAY or ABUS?

Do analysts recommend RLAY or ABUS?

Which has better earnings & valuation, RLAY or ABUS?

Which has more risk and volatility, RLAY or ABUS?

Does the media prefer RLAY or ABUS?

Is RLAY or ABUS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools